Physician profile
Arif Husain
NPI 1134507437
$3,124.38
in general payments reported to CMS, 2019-2025
28 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $429 · 2021: $1,095 · 2022: $1,077 · 2023: $188 · 2024: $66.07 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $632.57 | 2021-2025 | Xcopri |
| Ucb, INC. | $373.07 | 2020-2024 | Rystiggo |
| Biogen, INC. | $349.44 | 2020-2022 | |
| Eisai INC. | $328.02 | 2020-2021 | |
| Abbvie INC. | $253.73 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $142.92 | 2020-2022 | |
| Neurelis, INC. | $113.89 | 2020-2022 | |
| Acorda Therapeutics, INC | $102.57 | 2021-2022 | |
| Genzyme Corporation | $92.64 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $78.26 | 2022 | |
| Emd Serono, INC. | $70.08 | 2021 | |
| Lilly USA, LLC | $62.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $60.32 | 2022 | |
| Alexion Pharmaceuticals, INC. | $55.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.61 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.12 | 2021 | |
| Arbor Pharmaceuticals, INC. | $37.21 | 2021 | |
| Allergan, INC. | $35.93 | 2021 | |
| Lundbeck LLC | $33.78 | 2021 | |
| Acadia Pharmaceuticals INC | $31.89 | 2021-2022 | |
| Amgen INC. | $31.28 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $30.89 | 2022 | |
| Impel Pharmaceuticals INC. | $24.71 | 2022 | |
| Neurocrine Biosciences, INC. | $23.41 | 2020 | |
| Sumitomo Pharma America, INC. | $19.37 | 2023 | Aptiom |
| Celgene Corporation | $18.95 | 2022 | |
| Tg Therapeutics, INC. | $18.46 | 2023 | |
| Vanda Pharmaceuticals INC. | $18.42 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arif Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.